epidemica | systemic reviews
epidemica provides systematic reviews to expedite eu market access of innovative medicines
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-14869,ajax_fade,page_not_loaded,,vertical_menu_enabled, vertical_menu_transparency vertical_menu_transparency_on,qode-title-hidden,side_area_uncovered_from_content,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-4.3.5,vc_responsive


epidemica provides systematic reviews to expedite eu market access of innovative medicines


We are a networked team of expert professionals with in-depth experience across both the pharmaceutical industry and HEOR consulting. We conduct systematic reviews and meta-analyses that meet Health Technology Assessment methodological requirements.


Our first-hand experience of randomised controlled trials and economic evaluations as primary research enables us to better critique clinical and health economic literature during secondary research.


epidemica offers a process borne from years of experience, designed to deliver quality output within a specified budget and timescale, starting from the brief and protocol, through to final data presentation.


We offer a portfolio of inter-related disciplines, the combination of which provides in-depth assessment and full exploration of your decision problem.

Our services include:

  • RCT and non-RCT systematic reviews
  • Comparator mapping
  • Economic modelling inputs
  • Meta-analysis
  • NMA manuscripts


Our key strengths lie in the therapeutic areas of oncology (breast cancer in (neo)-adjuvant, metastatic first line, metastatic second or later line, HER2+/HER2- settings, TNBC, gastric and oesophageal cancer, SCCHN and renal cell carcinoma), CNS (schizophrenia, epilepsy, dementia, multiple sclerosis) and inflammatory diseases (ankylosing spondylitis and rheumatoid arthritis).

Latest papers

We’ve collected three example papers for you to review, including an interrogation of effect measure interpretation in major general medical journals, a cost systematic review in epilepsy and an RCT systematic review and network meta-analysis (NMA) publication in rheumatoid arthritis.

More papers will follow.

The images below will lead you to a synopsis of the papers and a link to the full version.